Foster & Motley Inc. Purchases 4,069 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Foster & Motley Inc. raised its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 38.4% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 14,656 shares of the biopharmaceutical company's stock after purchasing an additional 4,069 shares during the period. Foster & Motley Inc.'s holdings in Gilead Sciences were worth $1,642,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the company. Natixis Advisors LLC boosted its stake in shares of Gilead Sciences by 49.4% during the 1st quarter. Natixis Advisors LLC now owns 500,183 shares of the biopharmaceutical company's stock valued at $56,046,000 after purchasing an additional 165,446 shares in the last quarter. NorthRock Partners LLC grew its holdings in shares of Gilead Sciences by 3.8% during the 1st quarter. NorthRock Partners LLC now owns 11,632 shares of the biopharmaceutical company's stock worth $1,303,000 after acquiring an additional 425 shares during the period. Baader Bank Aktiengesellschaft grew its holdings in shares of Gilead Sciences by 21.0% during the 1st quarter. Baader Bank Aktiengesellschaft now owns 13,118 shares of the biopharmaceutical company's stock worth $1,453,000 after acquiring an additional 2,274 shares during the period. Mesirow Financial Investment Management Inc. raised its position in shares of Gilead Sciences by 6.3% in the 1st quarter. Mesirow Financial Investment Management Inc. now owns 7,434 shares of the biopharmaceutical company's stock worth $833,000 after acquiring an additional 442 shares in the last quarter. Finally, Arkadios Wealth Advisors lifted its stake in shares of Gilead Sciences by 94.6% in the 1st quarter. Arkadios Wealth Advisors now owns 45,750 shares of the biopharmaceutical company's stock valued at $5,126,000 after purchasing an additional 22,240 shares during the period. 83.67% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research firms have recently commented on GILD. Oppenheimer cut their target price on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a research note on Friday, April 25th. Cantor Fitzgerald assumed coverage on shares of Gilead Sciences in a research note on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 price objective for the company. Needham & Company LLC raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 target price for the company in a report on Friday, July 25th. Finally, Morgan Stanley increased their price target on shares of Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a report on Friday, April 25th. Eight research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $112.36.

Gilead Sciences Price Performance

Shares of NASDAQ GILD traded up $0.89 during mid-day trading on Friday, hitting $113.18. 5,016,320 shares of the stock traded hands, compared to its average volume of 5,285,206. The company has a market cap of $140.79 billion, a PE ratio of 23.83, a price-to-earnings-growth ratio of 0.71 and a beta of 0.33. Gilead Sciences, Inc. has a twelve month low of $72.43 and a twelve month high of $119.96. The company has a debt-to-equity ratio of 1.16, a current ratio of 1.37 and a quick ratio of 1.23. The firm has a 50 day simple moving average of $110.51 and a two-hundred day simple moving average of $106.80.

Insiders Place Their Bets

In other news, CEO Daniel Patrick O'day sold 10,000 shares of the company's stock in a transaction on Monday, July 28th. The shares were sold at an average price of $113.94, for a total value of $1,139,400.00. Following the completion of the sale, the chief executive officer owned 605,725 shares in the company, valued at $69,016,306.50. This represents a 1.62% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Jeffrey Bluestone sold 5,000 shares of the company's stock in a transaction on Monday, July 14th. The shares were sold at an average price of $109.74, for a total value of $548,700.00. Following the completion of the transaction, the director owned 8,920 shares of the company's stock, valued at $978,880.80. This trade represents a 35.92% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 82,000 shares of company stock worth $8,984,175 in the last quarter. 0.27% of the stock is currently owned by company insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.